Last checked at 5 Jan 2017 07:00
For immediate release 7.00am: 5 January 2017
HVIVO PLC
("hVIVO" or the "Company")
Directors' Dealings
hVIVO plc (AIM: HVO), a specialty biopharma company with clinical testing capabilities, announces that application has been made to AIM for the admission of 12,598 new ordinary shares of 5.0p each in the Company (the "New Ordinary Shares").
The New Ordinary Shares have been allotted pursuant to the purchase by Jaime Ellertson (Non-Executive Chairman) and Jim Winschel (Non-Executive Director) of new ordinary shares, under the terms of their letters of appointment as set out in the Company's announcement of 4 November 2014 which stated that Mr Ellertson and Mr Winschel had entered into binding commitments to purchase $20,000 and £4,000 of hVIVO plc new ordinary shares respectively per quarter. The New Ordinary Shares represent their investments for the quarter ended 31 December 2016. On 4 January 2017, Mr Ellertson invested in an additional 10,114 ordinary shares and Mr Winschel invested in an additional 2,484 ordinary shares, at a price of 161.0 pence per share.
Following admission of the New Ordinary Shares to trading on AIM, the total number of ordinary shares with voting rights in issue will be 78,113,675 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
Admission of the New Ordinary Shares ("Admission"), which will rank pari passu in all respects with the Company's existing shares in issue, is expected to occur on 9 January 2017. Following Admission, Mr Ellertson and Mr Winschel will be interested in a total of 65,154 and 37,190 ordinary shares of 5.0p in the Company respectively, each representing less than 0.1% of the Company's issued share capital.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 | Details of the persons discharging managerial responsibilities/persons closely associated | |
a) | Name | Jaime Ellertson and Jim Winschel |
2 | Reason for the notification | |
a) | Position/ status | Non-Executive Chairman and Non-Executive Director |
b) | Initial notification/ Amendment | Initial Notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||||
a) | Name | hVIVO plc | |||||||||
b) | Legal Entity Identifier | N/A | |||||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 5 pence each
GB00B6ZM0X53 | |||||||||
b) | Nature of the transaction | Acquisition of ordinary shares | |||||||||
c) | Currency | GBP | |||||||||
d) | Price(s) and volume(s) |
| |||||||||
e) | Aggregated information - Aggregated volume - Price - Aggregated total |
12,598 161.0p £20,282.78 | |||||||||
f) | Date of the transaction | 4 January 2017 | |||||||||
g) | Place of the transaction | London Stock Exchange, AIM | |||||||||
For further information please contact:
hVIVO plc +44 207 756 1300
Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial & Business Officer)
Media Enquiries +44 203 021 3933 / +44 7854 979 420
Colin Paterson (Director of Marketing, Communication and Public Relations)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
Notes to Editors:
hVIVO plc ("hVIVO"), a specialty biopharma company with clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 45 clinical studies, inoculated over 2000 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.